Blog

Nov 1, 2024, 07:21

Yaky Yanay: Pluri will be collaborating with BIRAD to advance cancer immunotherapy for solid tumors

Yaky Yanay, CEO and President at Pluri, shared a post by Pluri, on LinkedIn:

“I’m happy to share that Pluri will be collaborating with BIRAD to advance cancer immunotherapy for solid tumors, with the help of Cyrille Cohen Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan University.

This collaboration, recognized by the Israel Innovation Authority, holds great promise for developing more effective immunotherapies for patients with solid tumors. We would like to thank the IIA for their support in making this partnership possible. Together, we are driving innovation and transforming the future of cancer care!”

Quoting Pluri’s post:

“We’re excited to announce our collaboration with BIRAD, supported by the Israel Innovation Authority, to advance the continued development of MAIT Cells for solid tumors, led by Prof. Cyrille Cohen Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan University.

This partnership will integrate Prof. Cohen’s innovative Siglec-based Chimeric Switch Receptors into Pluri’s CAR-MAIT cell therapy platform, enhancing its efficacy and tumor specificity.

Together, we’re paving the way for breakthroughs in cancer care!
Read the full release by following the link.”

Yaky Yanay: Pluri will be collaborating with BIRAD to advance cancer immunotherapy for solid tumors

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond.

Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production.